Fresenius Kabi Completes Acquisition of Ivenix

Fresenius Kabi closed the acquisition announced in March of Ivenix, Inc. ('Ivenix'), a specialized infusion therapy company. Ivenix adds a next-generation infusion therapy platform for the significant U.S. market to Fresenius Kabi's portfolio and provides the company with key capabilities in hospital connectivity. The combination of Ivenix's leading hardware and software products with Fresenius Kabi's offering in intravenous fluids and infusion devices will create a comprehensive and leading portfolio of premium products, forming a strong basis to enable sustainable growth in the high-value MedTech space. The purchase price is a combination of US$240 million upfront payment and milestone payments, strictly linked to the achievement of commercial and operating targets.

Contact:

Fresenius SE & Co. KGaA

Else-Kroner-Str. 1

61352 Bad Homburg v.d.H.

Germany

T [phone]

[e-mail]

(C) 2022 Electronic News Publishing, source ENP Newswire